Perampanel as Adjunctive Therapy in Drug Resistant Epilepsy in Adolescents and Children Waiting for Epilepsy Surgery: A Multicenter Observational Study in Thailand
Abstract number :
3.512
Submission category :
7. Anti-seizure Medications / 7B. Clinical Trials
Year :
2023
Submission ID :
1228
Source :
www.aesnet.org
Presentation date :
12/4/2023 12:00:00 AM
Published date :
Authors :
Presenting Author: Piradee Suwanpakdee, MD – Phramongkutklao hospital
Burachat Saksritavee, MD – Phramongkutklao hospital; Napakjira Likasitthananon, MD – Phramongkutklao hospital; Thitiwan Simasathien, MD – Phramongkutklao hospital; Tayard Deesudchit, MD – Chulalongkorn University; Chaiyos Khongkhatithum, MD – Ramathibodi Hospital; Sorawit Viravan, MD – Siriraj Hospital; Charcrin Nabangchang, MD – Phramongkutklao hospital
Rationale:
This study aims to evaluate the effectiveness and tolerability of perampanel (PER) in real-world settings in patients between one month and 18 years of age with drug-resistant epilepsy (DRE) waiting for epilepsy surgery.
Methods:
In this multicenter study, patients between one month and 18 years of age with DRE treated with PER between January 2020 and June 2021 were selected. The study outcome was effectiveness of PER treatment reported as reduction in seizure frequency and seizure freedom rate. Effectiveness was assessed at 30, 60, 90, 120, 150, and 180 days after initiation of PER. Tolerability profiles were reported as adverse events according to the observations of the patients’ family members and physician.
Results:
Eighty-five patients treated with PER were included in the study. The mean initial dose and mean maximum dose of adjunctive PER was 2 mg/day and 5.8 mg/day, respectively. The mean seizure frequency (rate/week) was 41.3, 25.4, 18.9, 14.3, 11.2, 11.1, and 8.9 seizures at baseline, 30, 60, 90, 120, 150, and 180 days, respectively. The reduction in the mean seizure frequency at all timepoints was significant compared at the baseline (p < 0.001). At 180 days, ≥75% seizure reduction was seen in 64.9% (37/57) of the patients and seizure freedom was achieved in 36.8% (21/57). Drowsiness, ataxia, and behavioral changes were the common adverse events observed, and these improved after the dose of PER was reduced. No discontinuation of PER was required due to side effects or intolerance.
Anti-seizure Medications